Comparative Analysis of C-reactive Protein and Procalcitonin as Biomarkers for Prognostic Assessment in Pediatric Sepsis

被引:2
作者
Tyagi, Neha [1 ]
Gawhale, Siddhi [1 ]
Patil, Manojkumar G. [1 ]
Tambolkar, Sampada [1 ]
Salunkhe, Shradha [1 ]
Mane, Shailaja, V [1 ]
机构
[1] Dr DY Patil Vidyapeeth Deemed Be Univ Pimpri, Dr DY Patil Med Coll Hosp & Res Ctr, Pediat, Pune, India
关键词
prognostic utility; biomarkers; pediatric; procalcitonin; c-reactive protein; sepsis; CRITICALLY-ILL PATIENTS; MORTALITY;
D O I
10.7759/cureus.65427
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Sepsis poses a critical medical challenge due to its profound systemic inflammatory response, which frequently results in organ dysfunction and high mortality rates, especially in pediatric patients. The condition requires prompt recognition and aggressive management to mitigate its severe outcomes. Methods This prospective study enrolled 248 pediatric patients admitted with sepsis to the pediatric intensive care unit (PICU) at our tertiary care center. Patients were randomly assigned to either the C-reactive protein (CRP) or procalcitonin (PCT) groups, with biomarker levels measured upon admission (hour zero) and again at 72 hours post-admission. Clinical parameters such as the need for ionotropic support, use of steroids, incidence of acute kidney injury (AKI), requirement for invasive ventilation, patient outcomes, and changes in antibiotic management were assessed based on these biomarker levels. Results Procalcitonin-positive sepsis cases demonstrated notable clinical severity compared to their C-reactive protein counterparts, showing significantly lower systolic blood pressure (p = 0.012), heightened need for ionotropic support (p < 0.0001), and more pronounced liver and renal dysfunction as indicated by elevated serum bilirubin (p = 0.001) and creatinine levels (p = 0.0058). The incidence of AKI was also higher in procalcitonin-positive cases. Despite these severe clinical parameters, there were no significant differences in the length of the PICU stay or in patient outcomes concerning discharge and mortality rates. Procalcitonin levels effectively guided antibiotic management, resulting in therapy adjustments in a substantial proportion of cases, with 67 (54%) experiencing downgrades and 33 (27%) requiring upgrades based on procalcitonin levels measured 72 hours post-admission. Conclusion Procalcitonin proves to be a valuable biomarker in assessing the severity and management of sepsis in pediatric patients. It correlates significantly with clinical parameters such as blood pressure, the need for ionotropic support, and markers of organ dysfunction.
引用
收藏
页数:8
相关论文
共 16 条
  • [1] Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
    Bouadma, Lila
    Luyt, Charles-Edouard
    Tubach, Florence
    Cracco, Christophe
    Alvarez, Antonio
    Schwebel, Carole
    Schortgen, Frederique
    Lasocki, Sigismond
    Veber, Benoit
    Dehoux, Monique
    Bernard, Maguy
    Pasquet, Blandine
    Regnier, Bernard
    Brun-Buisson, Christian
    Chastre, Jean
    Wolff, Michel
    [J]. LANCET, 2010, 375 (9713) : 463 - 474
  • [2] Cleland DA, 2024, Procalcitonin
  • [3] Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial
    de Jong, Evelien
    van Oers, Jos A.
    Beishuizen, Albertus
    Vos, Piet
    Vermeijden, Wytze J.
    Haas, Lenneke E.
    Loef, Bert G.
    Dormans, Tom
    van Melsen, Gertrude C.
    Kluiters, Yvette C.
    Kemperman, Hans
    van den Elsen, Maarten J.
    Schouten, Jeroen A.
    Streefkerk, Joern O.
    Krabbe, Hans G.
    Kieft, Hans
    Kluge, Georg H.
    van Dam, Veerle C.
    van Pelt, Joost
    Bormans, Laura
    Otten, Martine Bokelman
    Reidinga, Auke C.
    Endeman, Henrik
    Twisk, Jos W.
    van de Garde, Ewoudt M. W.
    de Smet, Anne Marie G. A.
    Kesecioglu, Jozef
    Girbes, Armand R.
    Nijsten, Maarten W.
    de lange, Dylan W.
    [J]. LANCET INFECTIOUS DISEASES, 2016, 16 (07) : 819 - 827
  • [4] Utility of Procalcitonin as a Biomarker for Sepsis in Children
    Downes, Kevin J.
    Fitzgerald, Julie C.
    Weiss, Scott L.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2020, 58 (07)
  • [5] Diagnostic Challenges in Sepsis
    Duncan, Chris F.
    Youngstein, Taryn
    Kirrane, Marianne D.
    Lonsdale, Dagan O.
    [J]. CURRENT INFECTIOUS DISEASE REPORTS, 2021, 23 (12)
  • [6] Diagnosis of Neonatal Sepsis: The Role of Inflammatory Markers
    Eichberger, Julia
    Resch, Elisabeth
    Resch, Bernhard
    [J]. FRONTIERS IN PEDIATRICS, 2022, 10
  • [7] Incidence and prognosis of early hepatic dysfunction in critically ill patients - A prospective multicenter study
    Kramer, Ludwig
    Jordan, Barbara
    Druml, Wilfred
    Bauer, Peter
    Metnitz, Philipp G. H.
    [J]. CRITICAL CARE MEDICINE, 2007, 35 (04) : 1099 - 1104
  • [8] Multidrug-Resistant Sepsis: A Critical Healthcare Challenge
    Kumar, Nishitha R.
    Balraj, Tejashree A.
    Kempegowda, Swetha N.
    Prashant, Akila
    [J]. ANTIBIOTICS-BASEL, 2024, 13 (01):
  • [9] Relationship between gut microbiota dysbiosis and immune indicator in children with sepsis
    Lin, Xia
    Abdalla, Mohnad
    Yang, Junjie
    Liu, Lei
    Fu, Yali
    Zhang, Yanli
    Yang, Shuchun
    Yu, Han
    Ge, Yongsheng
    Zhang, Sufang
    Kang, Guiyun
    Dang, Wei
    Jiang, Qin
    Wang, Ying
    Gai, Zhongtao
    [J]. BMC PEDIATRICS, 2023, 23 (01)
  • [10] Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to the emergency department
    Magrini, Laura
    Gagliano, Giulia
    Travaglino, Francesco
    Vetrone, Francesco
    Marino, Rossella
    Cardelli, Patrizia
    Salerno, Gerardo
    Di Somma, Salvatore
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (10) : 1465 - 1472